SOURCE: Geneart AG

June 06, 2007 07:00 ET

GENEART Announces 1:1 Stock Dividend to Boost the Market Liquidity of its Stock

REGENSBURG, GERMANY--(Marketwire - June 6, 2007) -

- A proposal to issue a stock dividend will be submitted to a vote at
the Shareholders' Meeting on July 24, 2007.
- GENEART plans to double the share capital through a capital stock
increase from company funds in a 1:1 ratio.
- As a result, each shareholder would receive one additional share
for every held share.
- The stock issue does not involve the allocation of new
shareholders' equity.
Regensburg (Germany), June 06, 2007 - To boost the market liquidity of the company shares the members of the GENEART AG Board of Directors and the Advisory Board plan to suggest a 1:1 increase in capital stock from company funds at the Shareholders' Meeting on July 24, 2007. Each GENEART AG shareholder would receive one additional share for every held company share. The capital increase from company funds in the proposed amount doubles the company's share capital without an infusion of new shareholders' equity. The suggested issuing of one new ordinary share in the name of the holder for every already held share also doubles the number of company shares. After the increase in share capital from company funds, each ordinary share will retain its value of EUR 1.00.

Doubling the share capital and the number of traded ordinary shares is meant to boost the market liquidity of the GENEART shares and make them more attractive to a broader circle of investors. Pending the vote of the Shareholders' Meeting and subject to the prescribed terms, the new shares are expected to be issued in September. GENEART will make another announcement close to the issue date.

For further inquiries, please contact:

Bernd Merkl                    Frank Ostermair
GENEART AG                     Haubrok Investor Relations GmbH
Josef-Engert-Str. 11           Maximilianstraße 45
D-93053 Regensburg             80538 München
Tel.: +49-(0)941-942 76 - 38   Tel: +49-(0)89-21027-204
Fax: +49-(0)941-942 76 - 75    Fax: +49-(0)89-21027-298       


Founded in 1999, GENEART today is the globally leading specialists providing optimized gene solutions to research institutions as well as the pharma, biotech and chemical industries. GENEART offers integrated product systems based on gene synthesis for developing innovative drugs, in particular DNA- and protein-based therapeutics and vaccines, as well as for identifying improved industrial enzymes. The service portfolio ranges from the manufacturing of optimized synthetic genes in accordance with DIN EN ISO 9001:2000 and the generation of gene libraries in combinatorial biology, to the production and development of DNA-based drugs. GENEART, currently a team of more than 120 employees in Regensburg and the subsidiary in Toronto/Canada, reached break even in 2005 and is listed on the German Stock Exchange, Frankfurt, since May 2006.

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information